
Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.
Tanios Bekaii-Saab, MD, FACP, Mayo Clinic Cancer Center, talks about key takeaways from the phase 2 ReDOS clinical trial for specialty pharmacists.
Kohei Shitara, MD, Department of Gastrointestinal Oncology of National Cancer Center Hospital East, Japan, discusses the importance of the REVERCE clinical trial for specialty pharmacists.
Prior treatment with sorafenib followed by pembrolizumab (Keytruda) shows promising progression-free survival and overall survival in patients with advanced hepatocellular carcinoma.
Cetuximab (Erbitux) with pembrolizumab (Keytruda) shows promise in patients with mCRC.
Induction therapy shows the potential to achieve disease control in patients with locally advanced pancreatic cancer.
A novel CTC assay showed up to 88% accuracy detecting precancerous and cancerous colorectal lesions.
Nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy) induced responses in patients with heavily pretreated gastrointestinal stromal tumors.
The addition of ramucirumab did not improve overall survival in patients with HER2-negative gastric cancer.
A combination VEGFR-2 inhibitor plus an anti–PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Cabometyx found to improve median overall survival by 2.2 months in patients with previously treated advanced hepatocellular carcinoma.
There may not be a significant survival benefit from a surgical procedure for gastric cancer.
Median progression-free survival was 5.8 months among patients with HER2-positive gastric cancer who were treated with DS-8201.